Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins
MONDO:0013111Acute infantile liver failure due to mtDNA-encoded proteins synthesis defect is a very rare mitochondrial respiratory chain deficiency described in fewer than 10 infants, primarily of middle Eastern descent, and characterized clinically by transient but life-threatening liver failure with elevated liver enzymes, jaundice, vomiting, coagulopathy, hyperbilirubinemia, and lactic acidemia.
Also known as: acute infantile liver failure, LFIT, TRMU infantile liver failure, acute infantile liver failure due to synthesis defect of mitochondrial DNA-encoded proteins, acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins, infantile liver failure caused by mutation in TRMU, liver failure, infantile, transient, liver failure, transient infantile
22 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Stem-Cell liver machine tested in 12 patients
Disease control Recruiting nowThis early-phase trial is testing a new bioartificial liver device that uses liver cells grown from stem cells. It will be given to 12 people with liver failure or small-for-size syndrome. The main goal is to see if the treatment is safe and tolerable, while also checking for any…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Gut bacteria cocktail aims to help ailing livers
Disease control Recruiting nowThis early-stage trial is testing whether giving a mix of healthy gut bacteria (from donors) to people hospitalized with serious liver disease is safe and tolerable. The study involves 24 adults with liver failure or cirrhosis who have low levels of certain gut metabolites. Resea…
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to ease fatigue in mitochondrial disease
Symptom relief Recruiting nowThis Phase 2 trial tests whether KL1333 can reduce fatigue and improve leg strength in adults with primary mitochondrial disease, a genetic condition that affects energy production. About 180 participants will receive either KL1333 or a placebo twice daily for 48 weeks. The study…
Phase: PHASE2 • Sponsor: Pharming Technologies B.V. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
NIH launches study to uncover link between infections and mitochondrial disease
Knowledge-focused Recruiting nowThis study at the National Institutes of Health looks at how infections can worsen symptoms in people with mitochondrial disease, a group of disorders that affect energy production in cells. Researchers will evaluate participants' immune systems through blood tests, physical exam…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 02:00 UTC
-
Worldwide data pool could pave the way for mitochondrial disease trials
Knowledge-focused Recruiting nowThis study creates a global registry for people with mitochondrial disorders—rare diseases that affect energy production in cells. By collecting health data from 6,000 participants worldwide, researchers aim to understand how these diseases progress and identify the best ways to …
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists launch massive mitochondrial disease registry to unlock secrets of rare disorders
Knowledge-focused Recruiting nowThis study is creating a large registry and tissue bank for people with mitochondrial disorders. Researchers will collect medical information and samples from up to 1,000 participants, including those diagnosed with or suspected to have a mitochondrial disease. The goal is to gat…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Blood and skin samples could unlock new mitochondrial disease treatments
Knowledge-focused Recruiting nowThis study collects blood and skin samples from 100 people with primary mitochondrial diseases and healthy volunteers aged 3 to 85. Researchers will study how different mitochondrial mutations affect cell function and look for biomarkers. The samples will also help test a new the…
Sponsor: Minovia Therapeutics Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC